I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Journal ArticleDOI
After asthma: redefining airways diseases
Ian D. Pavord,Richard Beasley,Alvar Agusti,Gary P. Anderson,Elisabeth H. Bel,Guy Brusselle,Guy Brusselle,Paul Cullinan,Adnan Custovic,Francine M. Ducharme,John V. Fahy,Urs Frey,Peter G. Gibson,Peter G. Gibson,Liam G Heaney,Patrick G. Holt,Marc Humbert,Marc Humbert,Clare M. Lloyd,Guy B. Marks,Fernando D. Martinez,Peter D. Sly,Erika von Mutius,Sally E. Wenzel,Heather J. Zar,Andrew Bush +25 more
TL;DR: The only way to make progress in the future is to be much more clear about the meaning of the labels used for asthma and to acknowledge the assumptions associated with them, which are believed to be the most important causes of the stagnation in key clinical outcomes observed in the past 10 years.
Journal ArticleDOI
Treatable traits: toward precision medicine of chronic airway diseases.
Alvar Agusti,Elisabeth H. Bel,Mike Thomas,Claus Vogelmeier,Guy Brusselle,Guy Brusselle,Stephen T. Holgate,Marc Humbert,Paul W. Jones,Peter G. Gibson,Jørgen Vestbo,Richard Beasley,Ian D. Pavord +12 more
TL;DR: This Perspective proposes a precision medicine strategy for chronic airway diseases in general, and asthma and COPD in particular, and a discussion of the concept of “treatable traits” as a way towards precision medicine of chronicAirway diseases.
Journal ArticleDOI
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, double-blind, sham-controlled clinical trial
Mario Castro,Adalberto Sperb Rubin,Michel Laviolette,Jussara Fiterman,Marina Andrade Lima,Pallav L. Shah,Elie Fiss,Ronald Olivenstein,Neil C. Thomson,Robert Niven,Ian D. Pavord,Michael Simoff,David Duhamel,Charlene McEvoy,Richard G. Barbers,Nicolaas H T Ten Hacken,Michael E. Wechsler,Mark Holmes,Martin J. Phillips,Serpil C. Erzurum,William Lunn,Elliot Israel,Nizar N. Jarjour,Monica Kraft,Narinder S. Shargill,John Quiring,Scott M. Berry,Gerard Cox +27 more
TL;DR: BT in subjects with severe asthma improves asthma-specific quality of life with a reduction in severe exacerbations and healthcare use in the posttreatment period, and is superior in the BT group compared with sham.
Journal ArticleDOI
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
Steven Pascoe,Nicholas Locantore,Mark T. Dransfield,Mark T. Dransfield,Neil Barnes,Neil Barnes,Ian D. Pavord +6 more
TL;DR: Blood eosinophil count is a promising biomarker of response to inhaled corticosteroids in patients with COPD and could potentially be used to stratify patients for different exacerbation rate reduction strategies.
Journal ArticleDOI
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
Christopher E. Brightling,W Monteiro,R Ward,Debbie Parker,Mike Morgan,Andrew J. Wardlaw,Ian D. Pavord +6 more
TL;DR: It is suggested that eosinophilic airway inflammation contributes to airflow obstruction and symptoms in some patients with COPD and that the short-term effects of prednisolone are due to modification of this feature of the inflammatory response.